ChemoCentryx Inc (CCXI)

$ 10.72
-0.25 (-2.28%)
Buy
Symbol CCXI
Price $ 10.72
Beta 1.384
Volume Avg. 1.94M
Market Cap 0.75B
Shares () -
52 Week Range 9.55-70.29
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -8.57% Neutral
ROA -6.75% Neutral
Operating Margin -
Debt / Equity 38.26% Neutral
P/E -
P/B 2.05 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against ChemoCentryx, Inc. (CCXI) and July 6 Deadline

Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against ChemoCentryx, I...

NEW YORK--(BUSINESS WIRE)-- #CCXI--Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against ChemoCentryx, Inc. (CCXI) and July 6 Deadline ...

Business Wire
CCXI LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving ChemoCentryx, Inc.

CCXI LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving C...

New York, New York--(Newsfile Corp. - May 11, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased ChemoCentryx, Inc. ("ChemoCentryx") (NASDAQ: CCXI) between November 2... ...

Newsfile Corp
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against C...

LOS ANGELES, May 11, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ChemoCentryx, Inc. ("ChemoCentryx" or "the Company") (NASDAQ: CCXI) for violations of §... ...

PRNewsWire
CCXI Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies ChemoCentryx, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm

CCXI Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies ChemoCentryx, Inc. Shareholders of ...

NEW YORK, May 11, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ChemoCentryx, Inc. ("ChemoCentryx" or "the Company") (NASDAQ: CCXI) and certain of... ...

PRNewsWire
CCXI CLASS ACTION FILED: Contact HAGENS BERMAN to Recover Losses Due to Alleged Securities Fraud

CCXI CLASS ACTION FILED: Contact HAGENS BERMAN to Recover Losses Due to Alleged Securities Fraud

San Francisco, California--(Newsfile Corp. - May 11, 2021) - Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. A securities fraud class action is pending and certain investors may have ... ...

Newsfile Corp
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ChemoCentryx, Inc. - CCXI

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ChemoCentryx, In...

NEW YORK, May 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI).  Such investors are advised to contact Robert S. ...

PRNewsWire
CCXI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 6, 2021 in the Class Action Filed on Behalf of ChemoCentryx, Inc. Limited Shareholders

CCXI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 6, 2021 in the Class Acti...

New York, New York--(Newsfile Corp. - May 10, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ChemoCentryx, Inc. (NASDAQ: CCXI) alleging that the Company violated federal securities laws.... ...

Newsfile Corp
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of ChemoCentryx, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2021 - CCXI

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of ChemoCentryx, Inc. of a Class Acti...

New York, New York--(Newsfile Corp. - May 10, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of ChemoCentryx, Inc. ("ChemoCentryx") (NASDAQ: CCXI) be...

Newsfile Corp
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of ChemoCentryx, Inc. (CCXI) Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securiti...

LOS ANGELES--(BUSINESS WIRE)---- $CCXI #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired ... ...

Business Wire
CCXI INVESTOR ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages ChemoCentryx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - CCXI

CCXI INVESTOR ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages ChemoCentryx, Inc. Investors with Lo...

NEW YORK, May 10, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ChemoCentryx, Inc. (NASDAQ: CCXI) between November 26, 2019 and... ...

PRNewsWire

About


Dr. Thomas Schall
Healthcare
Biotechnology
Nasdaq Global Select

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.